Less than a year after a scandal embroiled its then China boss, pharma group AstraZeneca appears to have bounced back, maintaining sales and avoiding major fallout in the country.
在原中國區總裁卷入丑聞不到一年后，制藥巨頭阿斯利康(AstraZeneca)在中國似乎已重整旗鼓，還能保持原來的銷售額，避免了重大負面影響。
您已閱讀3%（249字），剩余97%（6971字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。